2018
A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma
Foss FM, Parker T. A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma. The Oncologist 2018, 23: 397-e30. PMID: 29438091, PMCID: PMC5896711, DOI: 10.1634/theoncologist.2017-0658.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaNon-Hodgkin lymphomaOverall response rateIntermediate-grade B-cellB cellsPartial responseResponse ratePhase I dose-escalation studyRefractory acute lymphoblastic leukemiaI dose-escalation studyT-cell non-Hodgkin lymphomaB-cell non-Hodgkin lymphomaPositron emission tomography scanSecond-generation purine nucleoside analogAggressive B-cell lymphomasPhase IDose of clofarabineGrade 3 leukopeniaLow-dose cohortMinimal hematologic toxicityRefractory acute leukemiaRefractory low gradeRefractory lymphoid malignanciesSingle-agent rituximab
2016
Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate.
Foss F, Parker T, Li A. Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate. Journal Of Clinical Oncology 2016, 34: 7558-7558. DOI: 10.1200/jco.2016.34.15_suppl.7558.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaSkin reactionsLymphomaMucositisLeucovorinPralatrexate
2012
Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma
Parker T, Barbarotta L, Girardi M, Foss F. Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma. Blood 2012, 120: 3660. DOI: 10.1182/blood.v120.21.3660.3660.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaRefractory cutaneous T-cell lymphomaRefractory peripheral T-cell lymphomaCutaneous toxicityMajority of patientsAdverse eventsMedian ageSkin flareMedian numberLow doseDiagnosis of PTCLCommon adverse eventsSpeakers bureauOff-label useIntravenous antibioticsCTCL patientsFirst doseToxic erythemaDose escalationCTCL lesionsMoist desquamationRetrospective reviewSkin breakdown